To The Moon
Home
News
TigerAI
Log In
Sign Up
Polar_
+Follow
Posts · 8
Posts · 8
Following · 0
Following · 0
Followers · 0
Followers · 0
Polar_
Polar_
·
2021-06-28
Hi, posting for coin
Sorry, this post has been deleted
看
858
回复
Comment
点赞
4
编组 21备份 2
Share
Report
Polar_
Polar_
·
2021-06-27
Hihihi
看
1.36K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Polar_
Polar_
·
2021-05-04
Hi
Uber, Pfizer, PayPal, T-Mobile, ViacomCBS, General Motors, and Other Stocks for Investors to Watch This Week
It’s another packed week of earnings reports, with 130 S&P 500 companies on deck to release their fi
Uber, Pfizer, PayPal, T-Mobile, ViacomCBS, General Motors, and Other Stocks for Investors to Watch This Week
看
947
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Polar_
Polar_
·
2021-04-09
Leggo
Sorry, this post has been deleted
看
1.75K
回复
1
点赞
4
编组 21备份 2
Share
Report
Polar_
Polar_
·
2021-03-23
Lets go
AstraZeneca to publish full trial data after U.S. rebuke
AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours a
AstraZeneca to publish full trial data after U.S. rebuke
看
1.77K
回复
5
点赞
5
编组 21备份 2
Share
Report
Polar_
Polar_
·
2021-03-19
Lets go
Toplines Before US Market Open on Friday
Stock futures rise, steadying after tech selloff.Nike, FedEx, Skillz, Ford & more making the biggest
Toplines Before US Market Open on Friday
看
1.55K
回复
1
点赞
3
编组 21备份 2
Share
Report
Polar_
Polar_
·
2021-03-18
Lets go
Why Wait for a Crash to Buy? These 3 Top Stocks Are Already Down More Than 40%
Investors love to be opportunistic. You can be sure the next time the market has a significant corre
Why Wait for a Crash to Buy? These 3 Top Stocks Are Already Down More Than 40%
看
1.27K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3576792612171267","uuid":"3576792612171267","gmtCreate":1613698588460,"gmtModify":1616077665693,"name":"Polar_","pinyin":"polarpolar","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":75,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":127557164,"gmtCreate":1624858600758,"gmtModify":1703846386803,"author":{"id":"3576792612171267","authorId":"3576792612171267","name":"Polar_","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576792612171267","idStr":"3576792612171267"},"themes":[],"htmlText":"Hi, posting for coin","listText":"Hi, posting for coin","text":"Hi, posting for coin","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127557164","repostId":"2146007118","repostType":4,"isVote":1,"tweetType":1,"viewCount":858,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127089500,"gmtCreate":1624803192600,"gmtModify":1703845352783,"author":{"id":"3576792612171267","authorId":"3576792612171267","name":"Polar_","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576792612171267","idStr":"3576792612171267"},"themes":[],"htmlText":"Hihihi","listText":"Hihihi","text":"Hihihi","images":[{"img":"https://static.tigerbbs.com/8770f59a44680603dca5078946b3d832","width":"1125","height":"2275"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127089500","isVote":1,"tweetType":1,"viewCount":1359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106031426,"gmtCreate":1620065019865,"gmtModify":1704338116831,"author":{"id":"3576792612171267","authorId":"3576792612171267","name":"Polar_","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576792612171267","idStr":"3576792612171267"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106031426","repostId":"1135819410","repostType":4,"repost":{"id":"1135819410","kind":"news","pubTimestamp":1619999342,"share":"https://ttm.financial/m/news/1135819410?lang=en_US&edition=fundamental","pubTime":"2021-05-03 07:49","market":"us","language":"en","title":"Uber, Pfizer, PayPal, T-Mobile, ViacomCBS, General Motors, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1135819410","media":"Barrons","summary":"It’s another packed week of earnings reports, with 130 S&P 500 companies on deck to release their fi","content":"<p>It’s another packed week of earnings reports, with 130 S&P 500 companies on deck to release their first-quarter results. Estée Lauder is among Monday’s highlights, before things pick up on Tuesday: Activision Blizzard, CVS Health, DuPont, Pfizer, and T-Mobile US all report.</p><p>On Wednesday, Barrick Gold, Booking Holdings, General Motors, PayPal Holdings, and Uber Technologies release earnings. Anheuser-Busch InBev, Moderna, Regeneron Pharmaceuticals, Square, and ViacomCBS go on Thursday. And finally, Cigna closes the week on Friday.</p><p><img src=\"https://static.tigerbbs.com/e1a866fbe5118566e68842053d76e2b9\" tg-width=\"1382\" tg-height=\"750\"></p><p>On the economic calendar this week, the main event will jobs Friday. The Bureau of Labor Statistics is forecast to report a gain of 975,000 nonfarm payrolls in April, and an unemployment rate of 5.8%—down from 6% a month earlier.</p><p>Other data out this week include the Institute for Supply Management’s Manufacturing Purchasing Managers’ Index for April on Monday and its Services equivalent on Wednesday.</p><p>Enterprise Products Partners and Estée Lauder release earnings.</p><p>Merck and Public Storage hold virtual investor days.</p><p><b>The Census Bureau</b> reports construction-spending data for March. Consensus estimate is for a 0.6% month-over-month increase in construction spending to a seasonally adjusted annual rate of $1.53 trillion.</p><p><b>The Institute for Supply</b> Management releases its Manufacturing Purchasing Managers’ Index for April. Economists forecast a 65 reading, roughly even with the March figure. The March reading was the highest for the index since December 1983.</p><p><b>Tuesday 5/4</b></p><p>Activision Blizzard,ConocoPhillips, Cummins, CVS Health,Dominion Energy,DuPont, Eaton, Pfizer,Sysco,and T-Mobile US report quarterly results.</p><p>Eli Lilly holds a conference call to discuss its sustainability initiatives.</p><p>Union Pacific holds its 2021 virtual investor day.</p><p><b>Wednesday 5/5</b></p><p>Barrick Gold, Booking Holdings,BorgWarner,Emerson Electric,General Motors,Hilton Worldwide Holdings,Novo Nordisk,PayPal Holdings, and Uber Technologies release earnings.</p><p><b>ADP releases</b> its National Employment Report for April. Expectations are for a gain of 762,500 jobs in private-sector employment after a 517,000 increase in March.</p><p><b>ISM releases</b> its Services PMI for April. The consensus call is for a 64.6 reading, a tick higher than the March data. The March reading was an all-time high for the index.</p><p><b>Thursday 5/6</b></p><p>Anheuser-Busch InBev,Becton Dickinson,Expedia Group,Fidelity National Information Services,Kellogg, Linde,MetLife,Moderna, Regeneron Pharmaceuticals, Square, ViacomCBS, and Zoetishold conference calls to discuss quarterly results.</p><p><b>The Department of Labor</b> reports initial jobless claims for the week ending on May 1. Initial jobless claims have averaged 611,750 a week in April and are at their lowest level since March of last year.</p><p><b>The Bureau of Labor</b> Statistics reports labor costs and productivity for the first quarter. Expectations are for a seasonally adjusted annual rate of 2.2% productivity growth, compared with a 4.2% decline in the fourth quarter of 2020. Unit labor costs are seen falling 0.4% after rising 6% previously.</p><p><b>Friday 5/7</b></p><p><b>The Bureau of Labor</b> Statistics releases the jobs report for April. Economists forecast a gain of 975,000 in nonfarm payroll employment. The unemployment rate is expected to edge down to 5.8% from 6%.</p><p>Cigna and <b>Liberty Media</b> report earnings.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uber, Pfizer, PayPal, T-Mobile, ViacomCBS, General Motors, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUber, Pfizer, PayPal, T-Mobile, ViacomCBS, General Motors, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 07:49 GMT+8 <a href=https://www.barrons.com/articles/uber-pfizer-paypal-t-mobile-viacomcbs-general-motors-and-other-stocks-for-investors-to-watch-this-week-51619982000?mod=hp_LEADSUPP_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s another packed week of earnings reports, with 130 S&P 500 companies on deck to release their first-quarter results. Estée Lauder is among Monday’s highlights, before things pick up on Tuesday: ...</p>\n\n<a href=\"https://www.barrons.com/articles/uber-pfizer-paypal-t-mobile-viacomcbs-general-motors-and-other-stocks-for-investors-to-watch-this-week-51619982000?mod=hp_LEADSUPP_2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PYPL":"PayPal","PFE":"辉瑞","TMUS":"T-Mobile US Inc",".IXIC":"NASDAQ Composite","UBER":"优步","GM":"通用汽车",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/uber-pfizer-paypal-t-mobile-viacomcbs-general-motors-and-other-stocks-for-investors-to-watch-this-week-51619982000?mod=hp_LEADSUPP_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135819410","content_text":"It’s another packed week of earnings reports, with 130 S&P 500 companies on deck to release their first-quarter results. Estée Lauder is among Monday’s highlights, before things pick up on Tuesday: Activision Blizzard, CVS Health, DuPont, Pfizer, and T-Mobile US all report.On Wednesday, Barrick Gold, Booking Holdings, General Motors, PayPal Holdings, and Uber Technologies release earnings. Anheuser-Busch InBev, Moderna, Regeneron Pharmaceuticals, Square, and ViacomCBS go on Thursday. And finally, Cigna closes the week on Friday.On the economic calendar this week, the main event will jobs Friday. The Bureau of Labor Statistics is forecast to report a gain of 975,000 nonfarm payrolls in April, and an unemployment rate of 5.8%—down from 6% a month earlier.Other data out this week include the Institute for Supply Management’s Manufacturing Purchasing Managers’ Index for April on Monday and its Services equivalent on Wednesday.Enterprise Products Partners and Estée Lauder release earnings.Merck and Public Storage hold virtual investor days.The Census Bureau reports construction-spending data for March. Consensus estimate is for a 0.6% month-over-month increase in construction spending to a seasonally adjusted annual rate of $1.53 trillion.The Institute for Supply Management releases its Manufacturing Purchasing Managers’ Index for April. Economists forecast a 65 reading, roughly even with the March figure. The March reading was the highest for the index since December 1983.Tuesday 5/4Activision Blizzard,ConocoPhillips, Cummins, CVS Health,Dominion Energy,DuPont, Eaton, Pfizer,Sysco,and T-Mobile US report quarterly results.Eli Lilly holds a conference call to discuss its sustainability initiatives.Union Pacific holds its 2021 virtual investor day.Wednesday 5/5Barrick Gold, Booking Holdings,BorgWarner,Emerson Electric,General Motors,Hilton Worldwide Holdings,Novo Nordisk,PayPal Holdings, and Uber Technologies release earnings.ADP releases its National Employment Report for April. Expectations are for a gain of 762,500 jobs in private-sector employment after a 517,000 increase in March.ISM releases its Services PMI for April. The consensus call is for a 64.6 reading, a tick higher than the March data. The March reading was an all-time high for the index.Thursday 5/6Anheuser-Busch InBev,Becton Dickinson,Expedia Group,Fidelity National Information Services,Kellogg, Linde,MetLife,Moderna, Regeneron Pharmaceuticals, Square, ViacomCBS, and Zoetishold conference calls to discuss quarterly results.The Department of Labor reports initial jobless claims for the week ending on May 1. Initial jobless claims have averaged 611,750 a week in April and are at their lowest level since March of last year.The Bureau of Labor Statistics reports labor costs and productivity for the first quarter. Expectations are for a seasonally adjusted annual rate of 2.2% productivity growth, compared with a 4.2% decline in the fourth quarter of 2020. Unit labor costs are seen falling 0.4% after rising 6% previously.Friday 5/7The Bureau of Labor Statistics releases the jobs report for April. Economists forecast a gain of 975,000 in nonfarm payroll employment. The unemployment rate is expected to edge down to 5.8% from 6%.Cigna and Liberty Media report earnings.","news_type":1,"symbols_score_info":{"UBER":0.9,".IXIC":0.9,"GM":0.9,".DJI":0.9,"PYPL":0.9,"PFE":0.9,"TMUS":0.9,".SPX":0.9,"VIACP":0.9}},"isVote":1,"tweetType":1,"viewCount":947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":348790235,"gmtCreate":1617959835727,"gmtModify":1704705325731,"author":{"id":"3576792612171267","authorId":"3576792612171267","name":"Polar_","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576792612171267","idStr":"3576792612171267"},"themes":[],"htmlText":"Leggo","listText":"Leggo","text":"Leggo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/348790235","repostId":"1168300924","repostType":4,"isVote":1,"tweetType":1,"viewCount":1752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353417239,"gmtCreate":1616512527321,"gmtModify":1704795173760,"author":{"id":"3576792612171267","authorId":"3576792612171267","name":"Polar_","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576792612171267","idStr":"3576792612171267"},"themes":[],"htmlText":"Lets go","listText":"Lets go","text":"Lets go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/353417239","repostId":"1176257801","repostType":4,"repost":{"id":"1176257801","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616512273,"share":"https://ttm.financial/m/news/1176257801?lang=en_US&edition=fundamental","pubTime":"2021-03-23 23:11","market":"us","language":"en","title":"AstraZeneca to publish full trial data after U.S. rebuke","url":"https://stock-news.laohu8.com/highlight/detail?id=1176257801","media":"Reuters","summary":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours a","content":"<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to publish full trial data after U.S. rebuke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to publish full trial data after U.S. rebuke\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-23 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176257801","content_text":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.\nThe rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.\nAstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.\nThe Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.\nIts shares were down 2.5% in London trading.\nThe U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.\nAnthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.\n“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.\n“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”\n‘NEGATIVE REPORTS’\nBesides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.\nThe new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.\n“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.\nRival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.\nThe panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.\nAstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.\nLater analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.\nCONFIDENCE HIT\nConfidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.\nThe European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.\nThe latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.\nAnalysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.\nStephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.\n“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”\nThe AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.\nIt has been granted conditional marketing or emergency use authorization in more than 70 countries.\nMany countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.","news_type":1,"symbols_score_info":{"AZN":0.9,"AZN.UK":0.9}},"isVote":1,"tweetType":1,"viewCount":1773,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575639261045142","authorId":"3575639261045142","name":"TerenceTan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3575639261045142","idStr":"3575639261045142"},"content":"help comment thx","text":"help comment thx","html":"help comment thx"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350304969,"gmtCreate":1616157346151,"gmtModify":1704791644504,"author":{"id":"3576792612171267","authorId":"3576792612171267","name":"Polar_","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576792612171267","idStr":"3576792612171267"},"themes":[],"htmlText":"Lets go","listText":"Lets go","text":"Lets go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/350304969","repostId":"1114755564","repostType":4,"repost":{"id":"1114755564","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1616156989,"share":"https://ttm.financial/m/news/1114755564?lang=en_US&edition=fundamental","pubTime":"2021-03-19 20:29","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1114755564","media":"Tiger Newspress","summary":"Stock futures rise, steadying after tech selloff.Nike, FedEx, Skillz, Ford & more making the biggest","content":"<ul><li>Stock futures rise, steadying after tech selloff.</li><li>Nike, FedEx, Skillz, Ford & more making the biggest moves in the premarket.</li></ul><p>(March 19) Stock futures edged higher Friday morning to recover some losses from Thursday's session, when another technology-led selloff dragged on the three major indexes.</p><p>At 8:24 a.m. ET, Futures for the Dow Jones Industrial Average up 25 points to 32,790.00, while the Standard & Poor’s 500 index futures rose 8 points at 3,914.00. Futures for the Nasdaq 100 index rose 59 points to 12,838.75.</p><p><img src=\"https://static.tigerbbs.com/3c1237210a3c58c82dd716380b12940e\" tg-width=\"349\" tg-height=\"145\" referrerpolicy=\"no-referrer\"></p><p>A day earlier, the Nasdaq slid by 3% for its worst session in three weeks as bond yields resurged. The 10-year Treasury yield spiked to the highest level since January 2020 and concerns over inflation reignited. The S&P 500 fell 1.5%, and the Dow dropped 0.5%.</p><p><b>Stocks making the biggest moves in the premarket: Nike, FedEx, Skillz, Ford & more</b></p><p>1) Nike(NKE) – Nike came in 14 cents a share above estimates, withquarterly profit of 90 cents per share. The athletic footwear and apparel company’s revenue came in below analysts’ projections, however, and its full-year revenue outlook was also shy of estimates. Nike said North American revenue was hit by port-related issues which delayed shipments by up to three weeks. Nike shares slid 3.2% in premarket trading.</p><p>2) FedEx(FDX) – FedExreported quarterly earnings of $3.47 per share, beating the consensus estimate of $3.23 a share. Revenue also came in above forecasts. FedEx’s average revenue per package for its Ground service rose by 11%, as it continues to benefit from the pandemic-related surge in e-commerce orders. Its shares jumped 4% in premarket action.</p><p>3) Skillz(SKLZ) – Skillz tumbled 7% in premarket action after the mobile gaming company announced a 32 million share public offering. The offering priced at $24 per share, with Skillz selling 17 million shares and certain stockholders selling the rest. Skillz said it would use the proceeds for general corporate purposes.</p><p>4) AstraZeneca(AZN) – AstraZeneca’s Covid-19 vaccine received the backing of Canada regulator Health Canada, which joined European countries in saying the vaccine is not linked to an increase in blood clots. Countries that had temporarily halted use of the vaccine have now resumed administering shots.</p><p>5) Hartford Financial(HIG) – The financial services company saidit is “carefully considering” a takeover proposalfrom insurance companyChubb(CB) for $65 per share or more than $23 billion. Hartford shares surged 18.7% Thursday following news of the offer, although it Is giving back about 1.4% in premarket trade.</p><p>6) Ollie’s Bargain Outlet(OLLI) – Ollie’s beat estimates by 14 cents a share, with quarterly earnings of 97 cents per share. The discount retailer’s revenue also came in above Wall Street forecasts. Comparable-store sales jumped 8.8%, beating the consensus FactSet forecast of a 3.2% increase. Ollie’s shares gained 4.6% in premarket trading.</p><p>7) Enphase(ENPH),SolarEdge Technologies(SEDG) – Susquehanna Financial upgraded both alternative energy stocks to “positive” from “neutral,” based on an anticipated expansion in solar installations in the years ahead and the strength of the two companies in the residential sector. Enphase rose 3.3% in the premarket, while SolarEdge gained 2.1%.</p><p>8) Ford Motor(F) – Ford shares are up 2.5% in premarket trading after Barclays upgraded the stock to “overweight” from “equal weight,” and increased its price target on the stock to $16 per share from $9. Barclays is encouraged by Ford’s developing electric vehicle strategy, among other factors.</p><p>9) Coherent(COHR) – The laser technology company remains on watch, as it mulls competing takeover bids fromLumentum(LITE) andII-VI(IIVI). Coherent first struck a deal to be acquired by Lumentum in January, but has received eight subsequent bids and revised offers since then.</p><p>10) Molson Coors(TAP) – The beer brewer’s stock fell 2.3% in premarket action after Deutsche Bank added it to its “short term sell catalyst” list. Deutsche Bank said the call is based on short-term concerns, including a material impact on first-quarter results from adverse February weather in Texas.</p><p>11) Petco Health(WOOF) – The pet supplies retailer was upgraded to “buy” from “neutral” at Bank of America Securities, saying Petco’s fourth-quarter results and 2021 were ahead of its expectations. The stock jumped 2.8% in premarket trading after losing 3.8% in Thursday trading.</p><p>12) Hims & Hers Health(HIMS) – Hims & Hers Health shares fell 3.3% in the premarket after the telehealth company reported a net quarterly loss of $3.1 million, even though that was smaller than the $12.4 million loss reported a year earlier. Revenue came in higher than anticipated, however, and total revenue was up by 80% for 2020.</p><p>13) Sarepta Therapeutics(SRPT) – The drugmaker’s shares rallied 5.4% in premarket trading after it reported upbeat results in a trial involving an experimental muscular dystrophy treatment.</p><p><b>Big News</b></p><p><b>1. Bond market rebels as it adjusts to Fed inflation polic</b></p><p>The10-year Treasury yieldpulled back Friday,one day after hitting a 14-month highof 1.754%.Traders revoltedover the Federal Reserve's willingness to let the economy and inflation to run hot as the job market recovers. Yields barely moved Wednesday afternoon after the Fed's meeting concluded, responding initially to the forecast for no rate hikes through 2023. The rapid rise in yields is being driven by concerns that more Covid stimulus on top of an already recovering economy will spark worrisome inflation. The 10-year yield started the year at less than 1%.</p><p><b>2. First U.S.-China meeting under Biden gets off to a rocky start</b></p><p>The first high-level meeting of U.S. and Chinese officials under the Biden administrationbegan with a flurry of insultsat a pre-meeting press event in Alaska on Thursday. The planned four-minute photo session for the officials to address reporters ended up lasting one hour and 15 minutes due to the frothy exchanges, according to NBC News. Expectations going in to the two-day talks, which are set to conclude Friday, were already low.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-03-19 20:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul><li>Stock futures rise, steadying after tech selloff.</li><li>Nike, FedEx, Skillz, Ford & more making the biggest moves in the premarket.</li></ul><p>(March 19) Stock futures edged higher Friday morning to recover some losses from Thursday's session, when another technology-led selloff dragged on the three major indexes.</p><p>At 8:24 a.m. ET, Futures for the Dow Jones Industrial Average up 25 points to 32,790.00, while the Standard & Poor’s 500 index futures rose 8 points at 3,914.00. Futures for the Nasdaq 100 index rose 59 points to 12,838.75.</p><p><img src=\"https://static.tigerbbs.com/3c1237210a3c58c82dd716380b12940e\" tg-width=\"349\" tg-height=\"145\" referrerpolicy=\"no-referrer\"></p><p>A day earlier, the Nasdaq slid by 3% for its worst session in three weeks as bond yields resurged. The 10-year Treasury yield spiked to the highest level since January 2020 and concerns over inflation reignited. The S&P 500 fell 1.5%, and the Dow dropped 0.5%.</p><p><b>Stocks making the biggest moves in the premarket: Nike, FedEx, Skillz, Ford & more</b></p><p>1) Nike(NKE) – Nike came in 14 cents a share above estimates, withquarterly profit of 90 cents per share. The athletic footwear and apparel company’s revenue came in below analysts’ projections, however, and its full-year revenue outlook was also shy of estimates. Nike said North American revenue was hit by port-related issues which delayed shipments by up to three weeks. Nike shares slid 3.2% in premarket trading.</p><p>2) FedEx(FDX) – FedExreported quarterly earnings of $3.47 per share, beating the consensus estimate of $3.23 a share. Revenue also came in above forecasts. FedEx’s average revenue per package for its Ground service rose by 11%, as it continues to benefit from the pandemic-related surge in e-commerce orders. Its shares jumped 4% in premarket action.</p><p>3) Skillz(SKLZ) – Skillz tumbled 7% in premarket action after the mobile gaming company announced a 32 million share public offering. The offering priced at $24 per share, with Skillz selling 17 million shares and certain stockholders selling the rest. Skillz said it would use the proceeds for general corporate purposes.</p><p>4) AstraZeneca(AZN) – AstraZeneca’s Covid-19 vaccine received the backing of Canada regulator Health Canada, which joined European countries in saying the vaccine is not linked to an increase in blood clots. Countries that had temporarily halted use of the vaccine have now resumed administering shots.</p><p>5) Hartford Financial(HIG) – The financial services company saidit is “carefully considering” a takeover proposalfrom insurance companyChubb(CB) for $65 per share or more than $23 billion. Hartford shares surged 18.7% Thursday following news of the offer, although it Is giving back about 1.4% in premarket trade.</p><p>6) Ollie’s Bargain Outlet(OLLI) – Ollie’s beat estimates by 14 cents a share, with quarterly earnings of 97 cents per share. The discount retailer’s revenue also came in above Wall Street forecasts. Comparable-store sales jumped 8.8%, beating the consensus FactSet forecast of a 3.2% increase. Ollie’s shares gained 4.6% in premarket trading.</p><p>7) Enphase(ENPH),SolarEdge Technologies(SEDG) – Susquehanna Financial upgraded both alternative energy stocks to “positive” from “neutral,” based on an anticipated expansion in solar installations in the years ahead and the strength of the two companies in the residential sector. Enphase rose 3.3% in the premarket, while SolarEdge gained 2.1%.</p><p>8) Ford Motor(F) – Ford shares are up 2.5% in premarket trading after Barclays upgraded the stock to “overweight” from “equal weight,” and increased its price target on the stock to $16 per share from $9. Barclays is encouraged by Ford’s developing electric vehicle strategy, among other factors.</p><p>9) Coherent(COHR) – The laser technology company remains on watch, as it mulls competing takeover bids fromLumentum(LITE) andII-VI(IIVI). Coherent first struck a deal to be acquired by Lumentum in January, but has received eight subsequent bids and revised offers since then.</p><p>10) Molson Coors(TAP) – The beer brewer’s stock fell 2.3% in premarket action after Deutsche Bank added it to its “short term sell catalyst” list. Deutsche Bank said the call is based on short-term concerns, including a material impact on first-quarter results from adverse February weather in Texas.</p><p>11) Petco Health(WOOF) – The pet supplies retailer was upgraded to “buy” from “neutral” at Bank of America Securities, saying Petco’s fourth-quarter results and 2021 were ahead of its expectations. The stock jumped 2.8% in premarket trading after losing 3.8% in Thursday trading.</p><p>12) Hims & Hers Health(HIMS) – Hims & Hers Health shares fell 3.3% in the premarket after the telehealth company reported a net quarterly loss of $3.1 million, even though that was smaller than the $12.4 million loss reported a year earlier. Revenue came in higher than anticipated, however, and total revenue was up by 80% for 2020.</p><p>13) Sarepta Therapeutics(SRPT) – The drugmaker’s shares rallied 5.4% in premarket trading after it reported upbeat results in a trial involving an experimental muscular dystrophy treatment.</p><p><b>Big News</b></p><p><b>1. Bond market rebels as it adjusts to Fed inflation polic</b></p><p>The10-year Treasury yieldpulled back Friday,one day after hitting a 14-month highof 1.754%.Traders revoltedover the Federal Reserve's willingness to let the economy and inflation to run hot as the job market recovers. Yields barely moved Wednesday afternoon after the Fed's meeting concluded, responding initially to the forecast for no rate hikes through 2023. The rapid rise in yields is being driven by concerns that more Covid stimulus on top of an already recovering economy will spark worrisome inflation. The 10-year yield started the year at less than 1%.</p><p><b>2. First U.S.-China meeting under Biden gets off to a rocky start</b></p><p>The first high-level meeting of U.S. and Chinese officials under the Biden administrationbegan with a flurry of insultsat a pre-meeting press event in Alaska on Thursday. The planned four-minute photo session for the officials to address reporters ended up lasting one hour and 15 minutes due to the frothy exchanges, according to NBC News. Expectations going in to the two-day talks, which are set to conclude Friday, were already low.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114755564","content_text":"Stock futures rise, steadying after tech selloff.Nike, FedEx, Skillz, Ford & more making the biggest moves in the premarket.(March 19) Stock futures edged higher Friday morning to recover some losses from Thursday's session, when another technology-led selloff dragged on the three major indexes.At 8:24 a.m. ET, Futures for the Dow Jones Industrial Average up 25 points to 32,790.00, while the Standard & Poor’s 500 index futures rose 8 points at 3,914.00. Futures for the Nasdaq 100 index rose 59 points to 12,838.75.A day earlier, the Nasdaq slid by 3% for its worst session in three weeks as bond yields resurged. The 10-year Treasury yield spiked to the highest level since January 2020 and concerns over inflation reignited. The S&P 500 fell 1.5%, and the Dow dropped 0.5%.Stocks making the biggest moves in the premarket: Nike, FedEx, Skillz, Ford & more1) Nike(NKE) – Nike came in 14 cents a share above estimates, withquarterly profit of 90 cents per share. The athletic footwear and apparel company’s revenue came in below analysts’ projections, however, and its full-year revenue outlook was also shy of estimates. Nike said North American revenue was hit by port-related issues which delayed shipments by up to three weeks. Nike shares slid 3.2% in premarket trading.2) FedEx(FDX) – FedExreported quarterly earnings of $3.47 per share, beating the consensus estimate of $3.23 a share. Revenue also came in above forecasts. FedEx’s average revenue per package for its Ground service rose by 11%, as it continues to benefit from the pandemic-related surge in e-commerce orders. Its shares jumped 4% in premarket action.3) Skillz(SKLZ) – Skillz tumbled 7% in premarket action after the mobile gaming company announced a 32 million share public offering. The offering priced at $24 per share, with Skillz selling 17 million shares and certain stockholders selling the rest. Skillz said it would use the proceeds for general corporate purposes.4) AstraZeneca(AZN) – AstraZeneca’s Covid-19 vaccine received the backing of Canada regulator Health Canada, which joined European countries in saying the vaccine is not linked to an increase in blood clots. Countries that had temporarily halted use of the vaccine have now resumed administering shots.5) Hartford Financial(HIG) – The financial services company saidit is “carefully considering” a takeover proposalfrom insurance companyChubb(CB) for $65 per share or more than $23 billion. Hartford shares surged 18.7% Thursday following news of the offer, although it Is giving back about 1.4% in premarket trade.6) Ollie’s Bargain Outlet(OLLI) – Ollie’s beat estimates by 14 cents a share, with quarterly earnings of 97 cents per share. The discount retailer’s revenue also came in above Wall Street forecasts. Comparable-store sales jumped 8.8%, beating the consensus FactSet forecast of a 3.2% increase. Ollie’s shares gained 4.6% in premarket trading.7) Enphase(ENPH),SolarEdge Technologies(SEDG) – Susquehanna Financial upgraded both alternative energy stocks to “positive” from “neutral,” based on an anticipated expansion in solar installations in the years ahead and the strength of the two companies in the residential sector. Enphase rose 3.3% in the premarket, while SolarEdge gained 2.1%.8) Ford Motor(F) – Ford shares are up 2.5% in premarket trading after Barclays upgraded the stock to “overweight” from “equal weight,” and increased its price target on the stock to $16 per share from $9. Barclays is encouraged by Ford’s developing electric vehicle strategy, among other factors.9) Coherent(COHR) – The laser technology company remains on watch, as it mulls competing takeover bids fromLumentum(LITE) andII-VI(IIVI). Coherent first struck a deal to be acquired by Lumentum in January, but has received eight subsequent bids and revised offers since then.10) Molson Coors(TAP) – The beer brewer’s stock fell 2.3% in premarket action after Deutsche Bank added it to its “short term sell catalyst” list. Deutsche Bank said the call is based on short-term concerns, including a material impact on first-quarter results from adverse February weather in Texas.11) Petco Health(WOOF) – The pet supplies retailer was upgraded to “buy” from “neutral” at Bank of America Securities, saying Petco’s fourth-quarter results and 2021 were ahead of its expectations. The stock jumped 2.8% in premarket trading after losing 3.8% in Thursday trading.12) Hims & Hers Health(HIMS) – Hims & Hers Health shares fell 3.3% in the premarket after the telehealth company reported a net quarterly loss of $3.1 million, even though that was smaller than the $12.4 million loss reported a year earlier. Revenue came in higher than anticipated, however, and total revenue was up by 80% for 2020.13) Sarepta Therapeutics(SRPT) – The drugmaker’s shares rallied 5.4% in premarket trading after it reported upbeat results in a trial involving an experimental muscular dystrophy treatment.Big News1. Bond market rebels as it adjusts to Fed inflation policThe10-year Treasury yieldpulled back Friday,one day after hitting a 14-month highof 1.754%.Traders revoltedover the Federal Reserve's willingness to let the economy and inflation to run hot as the job market recovers. Yields barely moved Wednesday afternoon after the Fed's meeting concluded, responding initially to the forecast for no rate hikes through 2023. The rapid rise in yields is being driven by concerns that more Covid stimulus on top of an already recovering economy will spark worrisome inflation. The 10-year yield started the year at less than 1%.2. First U.S.-China meeting under Biden gets off to a rocky startThe first high-level meeting of U.S. and Chinese officials under the Biden administrationbegan with a flurry of insultsat a pre-meeting press event in Alaska on Thursday. The planned four-minute photo session for the officials to address reporters ended up lasting one hour and 15 minutes due to the frothy exchanges, according to NBC News. Expectations going in to the two-day talks, which are set to conclude Friday, were already low.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,"SPY":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1545,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327826884,"gmtCreate":1616077335848,"gmtModify":1704790647187,"author":{"id":"3576792612171267","authorId":"3576792612171267","name":"Polar_","avatar":"https://static.tigerbbs.com/183a47fc422802518737f2f1f91acb93","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576792612171267","idStr":"3576792612171267"},"themes":[],"htmlText":"Lets go","listText":"Lets go","text":"Lets go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327826884","repostId":"1163358852","repostType":4,"repost":{"id":"1163358852","kind":"news","pubTimestamp":1616076828,"share":"https://ttm.financial/m/news/1163358852?lang=en_US&edition=fundamental","pubTime":"2021-03-18 22:13","market":"us","language":"en","title":"Why Wait for a Crash to Buy? These 3 Top Stocks Are Already Down More Than 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163358852","media":"nasdaq","summary":"Investors love to be opportunistic. You can be sure the next time the market has a significant corre","content":"<p>Investors love to be opportunistic. You can be sure the next time the market has a significant correction -- or even an inevitable crash -- that battle-tested investors won't flinch at taking advantage of lower prices. What if I told you that a lot of promising growth stocks have<i>already</i>crashed?</p><p>Shares of<b>Fastly</b>(NYSE: FSLY),<b>fuboTV</b>(NYSE: FUBO), and<b>Palantir Technologies</b>(NYSE: PLTR)have all fallen at least 40% from their 52-week highs. These aren't perfect stocks, but they're definitely not broken. Let's see why I think these are three investments are ripe for the picking in today's market climate.</p><p><b>1. Fastly</b></p><p>This next-gen content delivery network was rocking until the clock ran out on TikTok last year. Caught on the losing end of a trade war dispute between the U.S. and China late last year, Fastlylost a top accountthat was generating more than 10% of its revenue through the first nine months of last year -- and growing quickly, to boot.</p><p>There is life after TikTok, even if Fastly stock has shed nearly 45% of its value since topping out in October. Growth will slow from last year's 45% burst, but Fastly's guidance calls for decent 29% to 32% top-line growth in 2021. A recent acquisition is helping pad revenue gains, and Fastly's deficit will widen as it invests in new growth initiatives. This is far from a perfect company right now, but there's a lot to like here. Its net retention rate and dollar-based net expansion rate are slipping, but still comfortably over 100%. Fastly is keeping its customers happy, and there's no reason why the market believes that this is a little more than half the company it was five months ago.</p><p><b>2. fuboTV</b></p><p>We're cutting the cord, and live-TV streaming services are there to fill the void that the leading streaming services can't provide when it comes to live network programming. No one is growing faster than fuboTV in this niche, and it's stepping on the accelerator. Pro forma revenue rose 71% in the third quarter, 98% in the fourth quarter, and fuboTV's guidance calls for growth of 98% to 102% for the current quarter.</p><p>There are just545,000 subscribersright now, but they're a loyal and engaged lot of sports fans. Average revenue per user is up to $69.19 a month -- up 17% over the past year -- and that includes an industry-leading $8.47 a month in ad revenue. Why is this stock trading 49% below its December all-time high?</p><p>This isn't the only game to watch here. A pair of recent acquisitions will lead to a fantasy sports platform for members this summer and a more ambitious online sportsbook offering by the end of the year. If you think fuboTV's painting too rosy an outlook for 2021, keep in mind that it boosted its 2020 year-end guidance three times and it still found a way to come out on top.</p><p><b>3. Palantir</b></p><p>Palantir and Fastly may initially seem to have been separated at birth. Both companies grew revenue by 40% in their latest quarter, off from a pace in the mid-40% range for all of 2020 (up 45% for Fastly versus 47% for Palantir). Both stocks were slammed on uninspiring guidance. Palantir istargeting 30% growthfor 2021, roughly the midpoint of Fastly's outlook. Wall Street can be a rough crowd when 30%-ish growth brings out the boo birds.</p><p>Palantir's business model is naturally completely different than Fastly's. It's more ticktock than TikTok. Palantir's speciality is big-data business intelligence. It arms enterprises with actionable analysis from the data it collets. For better or worse more than half of Palantir's business comes from government contracts. It didn't generate a lot of buzz through its first few weeks of trading after last year'sIPO, but it certainly made up for lost time until peaking two months ago. It's been a 44% tumble from January's high. Palantir's valuation may have been overextended earlier this year, but this quality stock has gone from overbought to oversold in a hurry.</p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Wait for a Crash to Buy? These 3 Top Stocks Are Already Down More Than 40%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Wait for a Crash to Buy? These 3 Top Stocks Are Already Down More Than 40%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 22:13 GMT+8 <a href=https://www.nasdaq.com/articles/why-wait-for-a-crash-to-buy-these-3-top-stocks-are-already-down-more-than-40-2021-03-18><strong>nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors love to be opportunistic. You can be sure the next time the market has a significant correction -- or even an inevitable crash -- that battle-tested investors won't flinch at taking ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/why-wait-for-a-crash-to-buy-these-3-top-stocks-are-already-down-more-than-40-2021-03-18\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSLY":"Fastly, Inc.","PLTR":"Palantir Technologies Inc.","FUBO":"fuboTV Inc."},"source_url":"https://www.nasdaq.com/articles/why-wait-for-a-crash-to-buy-these-3-top-stocks-are-already-down-more-than-40-2021-03-18","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163358852","content_text":"Investors love to be opportunistic. You can be sure the next time the market has a significant correction -- or even an inevitable crash -- that battle-tested investors won't flinch at taking advantage of lower prices. What if I told you that a lot of promising growth stocks havealreadycrashed?Shares ofFastly(NYSE: FSLY),fuboTV(NYSE: FUBO), andPalantir Technologies(NYSE: PLTR)have all fallen at least 40% from their 52-week highs. These aren't perfect stocks, but they're definitely not broken. Let's see why I think these are three investments are ripe for the picking in today's market climate.1. FastlyThis next-gen content delivery network was rocking until the clock ran out on TikTok last year. Caught on the losing end of a trade war dispute between the U.S. and China late last year, Fastlylost a top accountthat was generating more than 10% of its revenue through the first nine months of last year -- and growing quickly, to boot.There is life after TikTok, even if Fastly stock has shed nearly 45% of its value since topping out in October. Growth will slow from last year's 45% burst, but Fastly's guidance calls for decent 29% to 32% top-line growth in 2021. A recent acquisition is helping pad revenue gains, and Fastly's deficit will widen as it invests in new growth initiatives. This is far from a perfect company right now, but there's a lot to like here. Its net retention rate and dollar-based net expansion rate are slipping, but still comfortably over 100%. Fastly is keeping its customers happy, and there's no reason why the market believes that this is a little more than half the company it was five months ago.2. fuboTVWe're cutting the cord, and live-TV streaming services are there to fill the void that the leading streaming services can't provide when it comes to live network programming. No one is growing faster than fuboTV in this niche, and it's stepping on the accelerator. Pro forma revenue rose 71% in the third quarter, 98% in the fourth quarter, and fuboTV's guidance calls for growth of 98% to 102% for the current quarter.There are just545,000 subscribersright now, but they're a loyal and engaged lot of sports fans. Average revenue per user is up to $69.19 a month -- up 17% over the past year -- and that includes an industry-leading $8.47 a month in ad revenue. Why is this stock trading 49% below its December all-time high?This isn't the only game to watch here. A pair of recent acquisitions will lead to a fantasy sports platform for members this summer and a more ambitious online sportsbook offering by the end of the year. If you think fuboTV's painting too rosy an outlook for 2021, keep in mind that it boosted its 2020 year-end guidance three times and it still found a way to come out on top.3. PalantirPalantir and Fastly may initially seem to have been separated at birth. Both companies grew revenue by 40% in their latest quarter, off from a pace in the mid-40% range for all of 2020 (up 45% for Fastly versus 47% for Palantir). Both stocks were slammed on uninspiring guidance. Palantir istargeting 30% growthfor 2021, roughly the midpoint of Fastly's outlook. Wall Street can be a rough crowd when 30%-ish growth brings out the boo birds.Palantir's business model is naturally completely different than Fastly's. It's more ticktock than TikTok. Palantir's speciality is big-data business intelligence. It arms enterprises with actionable analysis from the data it collets. For better or worse more than half of Palantir's business comes from government contracts. It didn't generate a lot of buzz through its first few weeks of trading after last year'sIPO, but it certainly made up for lost time until peaking two months ago. It's been a 44% tumble from January's high. Palantir's valuation may have been overextended earlier this year, but this quality stock has gone from overbought to oversold in a hurry.","news_type":1,"symbols_score_info":{"PLTR":0.9,"FSLY":0.9,"FUBO":0.9}},"isVote":1,"tweetType":1,"viewCount":1267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}